Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in the dose expansion ... HER3 is a protein expressed across several types of solid tumors, ...

ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia).

The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...

A precancerous cell is a cell with certain abnormalities that makes it more likely to become cancerous. These abnormalities don't mean that it will become cancer—in fact, most don't—but the diagnosis ...

1Triumvira Immunologics, Inc., headquartered in Austin, Texas, with research facilities in Hamilton, Canada.

Less frequently encountered genomic aberrations that have therapeutic potential include NRG, BRAF, NTRK, HER2, BRCA, PALB2, and claudin. Immune checkpoint inhibitors have unfortunately yielded ...

For more than a century, Times Union photographers have been documenting the Capital Region’s fascinating people, places and pivotal moments. About Contact Services Account ...

D. Boral Capital initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $9 price target Context is a pioneer in developing ...

Intracerebral hemorrhage (ICH) is a severe condition that devastatingly harms human health and poses a financial burden on families and society. Bcl-2 Associated X-protein (Bax) and B-cell lymphoma 2 ...